ATE44238T1 - Vakzine fuer gramnegative bakterien und verfahren zur herstellung derselben. - Google Patents

Vakzine fuer gramnegative bakterien und verfahren zur herstellung derselben.

Info

Publication number
ATE44238T1
ATE44238T1 AT84102119T AT84102119T ATE44238T1 AT E44238 T1 ATE44238 T1 AT E44238T1 AT 84102119 T AT84102119 T AT 84102119T AT 84102119 T AT84102119 T AT 84102119T AT E44238 T1 ATE44238 T1 AT E44238T1
Authority
AT
Austria
Prior art keywords
detoxified
gram
polysaccharide
negative bacterium
vaccine
Prior art date
Application number
AT84102119T
Other languages
German (de)
English (en)
Inventor
Grace C Tsay
Michael S Collins
Original Assignee
Miles Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Inc filed Critical Miles Inc
Application granted granted Critical
Publication of ATE44238T1 publication Critical patent/ATE44238T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/802—Antibody or antigen-binding fragment thereof that binds gram-positive bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT84102119T 1983-03-14 1984-02-29 Vakzine fuer gramnegative bakterien und verfahren zur herstellung derselben. ATE44238T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/475,415 US4663160A (en) 1983-03-14 1983-03-14 Vaccines for gram-negative bacteria
EP84102119A EP0118831B1 (en) 1983-03-14 1984-02-29 Vaccines for gram-negative bacteria and method for the preparation thereof

Publications (1)

Publication Number Publication Date
ATE44238T1 true ATE44238T1 (de) 1989-07-15

Family

ID=23887470

Family Applications (1)

Application Number Title Priority Date Filing Date
AT84102119T ATE44238T1 (de) 1983-03-14 1984-02-29 Vakzine fuer gramnegative bakterien und verfahren zur herstellung derselben.

Country Status (5)

Country Link
US (1) US4663160A (esLanguage)
EP (2) EP0306607A1 (esLanguage)
JP (1) JPS59175440A (esLanguage)
AT (1) ATE44238T1 (esLanguage)
DE (1) DE3478789D1 (esLanguage)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
AU584690B2 (en) * 1985-03-11 1989-06-01 Teijin Limited E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
DK163176C (da) * 1985-09-27 1992-06-22 Schweiz Serum & Impfinst Ugiftig konjugatvaccine mod infektioner af pseudomonas aeruginosa- og escherichia coli- bakterier, fremgangsmaade til fremstilling heraf og anvendelse af vaccinen
US4755381A (en) * 1986-03-27 1988-07-05 Swiss Serum And Vaccine Institute Berne Klebsiella capsular polysaccharide vaccine
US4789544A (en) * 1986-05-23 1988-12-06 Midcon Labs. Inc. Co-vaccination using non-O-carbohydrate side-chain gram-negative bacteria preparation
US5043158A (en) * 1987-08-21 1991-08-27 Chembiomed, Ltd. Immunogenic compositions containing ordered carriers
DE3727987A1 (de) * 1987-08-21 1989-03-02 Sleytr Uwe B Pharmazeutische struktur
US5063054A (en) * 1988-04-18 1991-11-05 Joseph Chang Microbial products used for treatment of hepatitis
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
JPH07503238A (ja) * 1992-01-16 1995-04-06 アメリカ合衆国 コレラ予防用の無毒化ｌｐｓ−コレラ毒素結合ワクチン
US5554730A (en) * 1993-03-09 1996-09-10 Middlesex Sciences, Inc. Method and kit for making a polysaccharide-protein conjugate
US5695768A (en) * 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
US5866132A (en) * 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
US6477464B2 (en) 2000-03-09 2002-11-05 Donnelly Corporation Complete mirror-based global-positioning system (GPS) navigation solution
US6329925B1 (en) 1999-11-24 2001-12-11 Donnelly Corporation Rearview mirror assembly with added feature modular display
US6693517B2 (en) 2000-04-21 2004-02-17 Donnelly Corporation Vehicle mirror assembly communicating wirelessly with vehicle accessories and occupants
WO2000003745A2 (en) 1998-07-15 2000-01-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
NZ509986A (en) * 1998-08-19 2003-10-31 Baxter Healthcare S Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines
US7370983B2 (en) 2000-03-02 2008-05-13 Donnelly Corporation Interior mirror assembly with display
US7167796B2 (en) 2000-03-09 2007-01-23 Donnelly Corporation Vehicle navigation system for use with a telematics system
US7581859B2 (en) 2005-09-14 2009-09-01 Donnelly Corp. Display device for exterior rearview mirror
US7255451B2 (en) 2002-09-20 2007-08-14 Donnelly Corporation Electro-optic mirror cell
WO2002062623A2 (en) 2001-01-23 2002-08-15 Donnelly Corporation Improved vehicular lighting system for a mirror assembly
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
AU2002309259A1 (en) 2002-05-09 2003-11-11 Massimo Porro Improved polysaccharide and glycoconjugate vaccines_____________
US7310177B2 (en) 2002-09-20 2007-12-18 Donnelly Corporation Electro-optic reflective element assembly
EP1549338B1 (en) 2002-10-11 2010-12-22 Novartis Vaccines and Diagnostics S.r.l. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
ES2383175T3 (es) 2003-01-30 2012-06-18 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
PL1670506T3 (pl) 2003-10-02 2013-04-30 Novartis Ag Płynne szczepionki przeciw wielu grupom serologicznym meningokoków
WO2005044861A1 (en) * 2003-10-31 2005-05-19 Wyeth Holdings Corporation Polysaccharides of helicobacter pylori
AU2005209303A1 (en) * 2004-01-29 2005-08-11 Biosynexus, Inc. Use of amino-oxy functional groups in the preparation of vaccines conjugates
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
WO2005105140A2 (en) 2004-04-30 2005-11-10 Chiron Srl Meningococcal conjugate vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
US8246993B2 (en) * 2004-06-10 2012-08-21 Cytogel Pharma, Llc Advantageous hydrogel composition
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
US20060013886A1 (en) 2004-06-28 2006-01-19 Daqing Wu Injectable microspheres
US20060062779A1 (en) 2004-09-21 2006-03-23 The Brigham And Women's Hospital, Inc. Methods and compositions relating to mannuronic acid specific binding peptides
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
PL2004225T3 (pl) 2006-03-22 2012-09-28 Novartis Ag Schematy immunizacji koniugatami meningokokowymi
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
US8956625B2 (en) 2006-09-07 2015-02-17 Glaxosmithkline Biologicals, S.A. Inactivated polio vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
JP2010525035A (ja) 2007-05-02 2010-07-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0713880D0 (en) * 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US8017898B2 (en) 2007-08-17 2011-09-13 Magna Electronics Inc. Vehicular imaging system in an automatic headlamp control system
WO2009046268A1 (en) 2007-10-04 2009-04-09 Magna Electronics Combined rgb and ir imaging sensor
BR122016015627A2 (pt) 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CA2716212A1 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
ES2586308T3 (es) 2008-10-27 2016-10-13 Glaxosmithkline Biologicals Sa Procedimiento de purificación de un hidrato de carbono de Streptococcus del grupo A
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
WO2010070453A2 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
CN102438649A (zh) 2009-03-24 2012-05-02 诺华有限公司 脑膜炎球菌h因子结合蛋白和肺炎球菌结合糖的组合物
CA2758490C (en) 2009-04-14 2023-05-02 Novartis Ag Compositions for immunising against staphylococcus aureus
WO2011017101A2 (en) 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
EP3017828A1 (en) 2009-08-27 2016-05-11 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
EP2475385A1 (en) 2009-09-10 2012-07-18 Novartis AG Combination vaccines against respiratory tract diseases
RU2603267C2 (ru) 2009-09-30 2016-11-27 Новартис Аг Конъюгация капсульных полисахаридов staphylococcus aureus типа 5 и типа 8
EP2483390A2 (en) 2009-09-30 2012-08-08 Novartis AG Expression of meningococcal fhbp polypeptides
CN102917730A (zh) 2009-10-27 2013-02-06 诺华有限公司 修饰的脑膜炎球菌fHBP多肽
CA2779578A1 (en) * 2009-10-30 2011-05-05 Novartis Ag Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
CN102892753B (zh) 2009-12-17 2016-01-20 法纳生物解决办法有限责任公司 在制备缀合疫苗中用于活化多糖的化学试剂
JP5781542B2 (ja) 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
EP2574172A4 (en) 2010-05-21 2013-10-30 Cytogel Pharma Llc MATERIALS AND METHOD FOR TREATING INFLAMMATION
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
CA2828844C (en) 2011-03-02 2020-07-14 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
RU2636350C2 (ru) 2011-11-07 2017-11-22 Новартис Аг МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
RS56709B1 (sr) 2011-12-06 2018-03-30 Valneva Austria Gmbh Jedinjenja aluminijuma za primenu u terapeuticima i vakcinama
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
JP2015505309A (ja) 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
US9777076B2 (en) 2012-07-16 2017-10-03 Pfizer Inc. Saccharides and uses thereof
CA2882619A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
CN105307684A (zh) 2012-10-02 2016-02-03 葛兰素史密丝克莱恩生物有限公司 非直链糖缀合物
CN104918634A (zh) 2012-10-12 2015-09-16 葛兰素史密丝克莱恩生物有限公司 用于组合疫苗的非交联无细胞百日咳抗原
EP2925355B1 (en) 2012-11-30 2017-11-15 GlaxoSmithKline Biologicals S.A. Pseudomonas antigens and antigen combinations
ES2670863T3 (es) 2013-02-01 2018-06-01 Glaxosmithkline Biologicals Sa Administración intradérmica de composiciones inmunológicas que comprenden agonistas del receptor de tipo Toll
JP2017501990A (ja) * 2013-12-03 2017-01-19 ヴァイロメティックス アーゲー 肺炎連鎖球菌（Ｓ．ｐｎｅｕｍｏｎｉａｅ）に対して防御的なプロリンリッチペプチド
RS61246B1 (sr) 2014-02-28 2021-01-29 Glaxosmithkline Biologicals Sa Modifikovani meningokokni fhbp polipeptidi
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
US12161707B2 (en) 2016-09-02 2024-12-10 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
US20210108002A1 (en) 2016-12-06 2021-04-15 Glaxosmithkline Biologicals Sa Purification Process For Capsular Polysaccharide
AU2018290298B2 (en) * 2017-06-23 2024-03-28 Affinivax, Inc. Immunogenic compositions
US10975121B2 (en) 2017-06-24 2021-04-13 Cytogel Pharma, Llc Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
GB202013262D0 (en) 2020-08-25 2020-10-07 Glaxosmithkline Biologicals Sa Vaccine Composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH396316A (de) * 1960-07-12 1965-07-31 Wander Ag Dr A Verfahren zur Herstellung von Impfstoffen
US3987164A (en) * 1970-10-20 1976-10-19 Yuzuru Homma Method for prevention of pseudomonas aeruginosa infections
US4185090A (en) * 1972-02-02 1980-01-22 Abbott Laboratories Chemically modified endotoxin immunizing agent
JPS519714A (esLanguage) * 1974-06-04 1976-01-26 Wellcome Found
JPS51106714A (esLanguage) * 1975-03-12 1976-09-21 Tokyo Daigaku
JPS5296729A (en) * 1976-02-05 1977-08-13 Shionogi & Co Ltd Mixed vaccin for cyanomycosis
FR2460139A1 (fr) * 1979-06-29 1981-01-23 Pasteur Institut Fraction antigenique glycopeptidique vaccinante a tres grande immunogenicite isolee de cultures de germes pathogenes, procedes d'isolement de cette fraction et vaccins contenant ladite fraction
JPS5639022A (en) * 1979-09-05 1981-04-14 Hayashibara Biochem Lab Inc Preparation of vaccine
US4285936A (en) * 1979-12-10 1981-08-25 The United States Of America As Represented By The Secretary Of The Army Method for producing a vaccine against bacterial infections caused by pseudomonas aeruginosa
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine

Also Published As

Publication number Publication date
EP0306607A1 (en) 1989-03-15
EP0118831A2 (en) 1984-09-19
JPS59175440A (ja) 1984-10-04
US4663160A (en) 1987-05-05
DE3478789D1 (en) 1989-08-03
EP0118831B1 (en) 1989-06-28
EP0118831A3 (en) 1986-12-10
JPH0577657B2 (esLanguage) 1993-10-27

Similar Documents

Publication Publication Date Title
ATE44238T1 (de) Vakzine fuer gramnegative bakterien und verfahren zur herstellung derselben.
SE7708845L (sv) Framstellning av d(-)-3-hydroxismorsyra
ATE264326T1 (de) Verfahren zur herstellung von imidazochinolinaminen
DE69826851D1 (de) Kopplung unmodifizierter proteinen an haloacyl- oder dihaloacyl-derivatisierten polysacchariden zur herstellung von protein-polysaccharide impfstoffen
ATE155172T1 (de) Verfahren zur herstellung einer mehrfach ungesättigten fettsäure des omega 9 typs
ATE109202T1 (de) Avirulenter vibrio cholerae und verfahren zu seiner herstellung.
IE810618L (en) Pasteurella vaccines
DE69112716D1 (de) Verfahren zur biologischen Herstellung einer Hydroxyvitamin-D-Verbindung.
ATE30713T1 (de) Isolierung von enzymatisch erzeugten carbonsaeuren.
EP0090660A3 (en) Neisseria gonorrhoeae vaccine
ATE80602T1 (de) Verfahren zur herstellung von hydroxybiphenylen.
DE68912236D1 (de) Verfahren zur Herstellung von hochgradig ungesättigten Fettsäuren.
ATE127470T1 (de) Verfahren zur herstellung von phosphatidylcholinderivaten.
DE69531690D1 (de) Reinigungsverfahren für von bordetella produziertem nekrotoxin
DE3769425D1 (de) Verfahren zur herstellung eines abgasfuehlers.
KR840002855A (ko) Omt에스테르 유도체의 제조방법
DE69530959D1 (de) Verfahren zur Herstellung einer L-Aminosäure
DE3163814D1 (en) Homocitric acid oligoriboside derivatives, process for their manufacture and their use as preventives of dental caries
DE3877510D1 (de) Verfahren zur herstelllung von brenztraubensaeure.
ATE66151T1 (de) Verfahren zur herstellung von intravenoes geeigneten immunoglobulinen.
ATE121746T1 (de) Verfahren zur herstellung bissilylierter 3- iodmethylcephalosporinderivaten.
DE3583830D1 (de) Nortriptylinderivate, verfahren zu ihrer herstellung, deren konjugate mit antigenischen proteinen und enzymen, antikoerper davon und verwandte verfahren zur bestimmung.
SE8403929L (sv) Rekombinant-dna-molekyl, transformerade mikroorganismer och forfarande for framstellning av penicillin v-amidas
KR830007668A (ko) 6-아미노페니실란산 유도체의 제조방법
ATE21033T1 (de) Verfahren zur herstellung eines immunogens aus pasteurella multocida.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee